Multi-year contract with top five global pharma

RNS Number : 5613O

Diaceutics PLC

13 June 2022

 

13 June 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Multi-year contract win with top five global pharma company

US$2m+ contract to deliver customised data insights via the DXRX platform

Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, intelligence, and analytics on the healthcare market is pleased to announce that it has secured a multi -year deal with a top five global pharma company to deliver customised data insights via the DXRX platform.

The three-year enterprise deal, which is in excess of US$2m in aggregate, is a notable upsell win for Diaceutics, which has been working with the client since 2014, and supports the move towards enhanced multi-year recurring revenues, a key strategy for the Company going forward.

Under the terms of this new agreement, Diaceutics will provide c omprehensive mapping and analysis of US physicians and labs who perform testing for non-small cell lung cancer (NSCLC). This holistic view of the NSCLC space in which labs are performing biomarker specific diagnostic testing means patients can be linked to targeted therapies in this disease area.

In addition, Diaceutics will also correlate these labs to corresponding physician testing behaviours, providing an understanding of testing rates, methodologies and the overall relationship between these two key stakeholder groups.

Jordan Clark, Chief Commercial Officer of Diaceutics commented:

"This win is testament to the value of our DXRX platform, proving that our platform continues to gain traction within the marketplace, elevating our profile and putting us in a prime position to continue to win large, long-term contracts.

"As the treatment of cancer has become progressively more biomarker-driven, and with the rapid emergence of effective matched targeted therapies, pharma companies are making attempts to define best practices for which tests are necessary and in what target population. The DXRX intelligence will be a vital tool in enabling our customer to achieve this and optimising their sales territories."

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: [phone]
Caroline Forde	[e-mail]
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

 

END

 

 

CNTUUOKRUNUNAAR